 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase or decrease the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMBISOME increase the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMBISOME increase the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMBISOME increase the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"AMBISOME"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: AMBISOME: adverse_reactions: Metabolic & Nutritional Disorders Acidosis, amylase increased, hyperchloremia, hyperkalemia, hypermagnesemia, hyperphosphatemia, hyponatremia, hypophosphatemia, [0m
[31mhypoproteinemia, lactate dehydrogenase increased, nonprotein nitrogen [0m[1;31m([0m[31mNPN[0m[1;31m)[0m[31m increased, and respiratory alkalosis. Musculoskeletal System Arthralgia, bone pain, dystonia, myalgia, and rigors. Nervous [0m
[31mSystem Agitation, coma, convulsion, cough, depression, dysesthesia, dizziness, hallucinations, nervousness, paresthesia, somnolence, thinking abnormality, and tremor. Respiratory System Asthma, [0m
[31matelectasis, hemoptysis, hiccup, hyperventilation, influenza-like symptoms, lung edema, pharyngitis, pneumonia, respiratory insufficiency, respiratory failure, and sinusitis. AMBISOME: [0m
[31madverse_reactions: Skin & Appendages Alopecia, dry skin, herpes simplex, injection site inflammation, maculopapular rash, purpura, skin discoloration, skin disorder, skin ulcer, urticaria, and [0m
[31mvesiculobullous rash. Special Senses Conjunctivitis, dry eyes, and eye hemorrhage. Urogenital System Abnormal renal function, acute kidney failure, acute renal failure, dysuria, kidney failure, toxic [0m
[31mnephropathy, urinary incontinence, and vaginal hemorrhage. Post-marketing Experience The following infrequent adverse experiences have been reported in post-marketing surveillance, in addition to [0m
[31mthose mentioned above: angioedema, erythema, urticaria, bronchospasm, cyanosis/hypoventilation, pulmonary edema, agranulocytosis, hemorrhagic cystitis, and rhabdomyolysis. AMBISOME: adverse_reactions:[0m
[31mClinical Laboratory Values The effect of Am B isome on renal and hepatic function and on serum electrolytes was assessed from laboratory values measured repeatedly in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m. The frequency and[0m
[31mmagnitude of hepatic test abnormalities were similar in the Am B isome and amphotericin B groups. Nephrotoxicity was defined as creatinine values increasing [0m[1;31m100[0m[31m% or more over pretreatment levels in [0m
[31mpediatric patients, and creatinine values increasing [0m[1;31m100[0m[31m% or more over pretreatment levels in adult patients, provided the peak creatinine concentration was > [0m[1;31m1.2[0m[31m mg/dL. Hypokalemia was defined as [0m
[31mpotassium levels â‰¤ [0m[1;31m2.5[0m[31m mmol/L any time during treatment. AMBISOME: adverse_reactions: Incidence of nephrotoxicity, mean peak serum creatinine concentration, mean change from baseline in serum [0m
[31mcreatinine, and incidence of hypokalemia in the double-blind, randomized study were lower in the Am B isome group as summarized in the following table: Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m Laboratory Evidence of [0m
[31mNephrotoxicity AmBisome [0m[1;31m3[0m[31m mg/kg/day Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m343[0m[31m [0m[1;31m344[0m[31m Nephrotoxicity [0m[1;31m64[0m[31m [0m[1;31m([0m[1;31m18.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m116[0m[31m [0m[1;31m([0m[1;31m33.7[0m[31m%[0m[1;31m)[0m[31m Mean peak creatinine [0m
[1;31m1.24[0m[31m mg/dL [0m[1;31m1.52[0m[31m mg/dL Mean change from baseline in creatinine [0m[1;31m0.48[0m[31m mg/dL [0m[1;31m0.77[0m[31m mg/dL Hypokalemia [0m[1;31m23[0m[31m [0m[1;31m([0m[1;31m6.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m40[0m[31m [0m[1;31m([0m[1;31m11.6[0m[31m%[0m[1;31m)[0m[31m The effect of Am B isome [0m[1;31m([0m[1;31m3[0m[31m mg/kg/day[0m[1;31m)[0m[31m vs. AMBISOME: adverse_reactions: [0m
[31mamphotericin B [0m[1;31m([0m[1;31m0.6[0m[31m mg/kg/day[0m[1;31m)[0m[31m on renal function in adult patients enrolled in this study is illustrated in the following figure: In empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, the incidence of nephrotoxicity [0m
[31mas measured by increases of serum creatinine from baseline was significantly lower for patients administered Am B isome [0m[1;31m([0m[31mindividual dose groups and combined[0m[1;31m)[0m[31m compared with amphotericin B lipid [0m
[31mcomplex. Incidence of Nephrotoxicity Empirical Therapy Study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m AmBisome Amphotericin B lipid complex [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m3[0m[31m mg/kg/day [0m[1;31m5[0m[31m mg/kg/day BOTH Total number of patients [0m[1;31m85[0m[31m [0m[1;31m81[0m[31m [0m[1;31m166[0m[31m [0m[1;31m78[0m[31m Number with [0m
[31mnephrotoxicity [0m[1;31m1.[0m[31m5X baseline serum creatinine value [0m[1;31m25[0m[31m [0m[1;31m([0m[1;31m29.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m21[0m[31m [0m[1;31m([0m[1;31m25.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m27.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m62[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m8[0m[31m%[0m[1;31m)[0m[31m 2X baseline serum creatinine value [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m14.1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m14.8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m33[0m[31m [0m
[1;31m([0m[1;31m42.3[0m[31m%[0m[1;31m)[0m[31m The following graph shows the average serum creatinine concentrations in the compassionate use study and shows that there is a drop from pretreatment concentrations for all patients, [0m
[31mespecially those with elevated [0m[1;31m([0m[31mgreater than [0m[1;31m1.7[0m[31m mg/dL[0m[1;31m)[0m[31m pretreatment creatinine concentrations. The incidence of nephrotoxicity in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m comparative trial in cryptococcal meningitis was lower[0m
[31min the Am B isome groups as shown in the following table: Laboratory Evidence of Nephrotoxicity Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0[0m[31m. AMBISOME: adverse_reactions: [0m
[1;31m7[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m86[0m[31m [0m[1;31m94[0m[31m [0m[1;31m87[0m[31m Number with Nephrotoxicity [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m. AMBISOME: adverse_reactions: 5X baseline serum creatinine [0m[1;31m30[0m[31m [0m[1;31m([0m[1;31m35[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m47[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m
[1;31m([0m[1;31m60[0m[31m%[0m[1;31m)[0m[31m 2X baseline serum creatinine [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m20[0m[31m [0m[1;31m([0m[1;31m21[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m33[0m[31m%[0m[1;31m)[0m[31m Mean Change in Creatinine Over Time in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m Mean Creatine Concentrations Over Time         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions: [0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m57.7[0m[31m%[0m[1;31m)[0m[31m Nausea [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m10.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m8.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m9.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m Vomiting [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m5.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m6.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m14.1[0m[31m%[0m[1;31m)[0m[31m Hypertension [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m8.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m15.4[0m[31m%[0m[1;31m)[0m[31m [0m
[31mTachycardia [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m2.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m14[0m[31m [0m[1;31m([0m[1;31m17.9[0m[31m%[0m[1;31m)[0m[31m Dyspnea [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m7.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m10.3[0m[31m%[0m[1;31m)[0m[31m Hypoxia [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m11[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m Day [0m[1;31m1[0m[31m body temperature increased [0m
[31mabove the temperature taken within [0m[1;31m1[0m[31m hour prior to infusion [0m[1;31m([0m[31mpreinfusion temperature[0m[1;31m)[0m[31m or above the lowest infusion value [0m[1;31m([0m[31mno preinfusion temperature recorded[0m[1;31m)[0m[31m. Patients were not administered [0m
[31mpremedications to prevent infusion-related reactions prior to the Day [0m[1;31m1[0m[31m study drug infusion. In Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m, a randomized, double-blind, multicenter trial comparing Am B isome and amphotericin B [0m
[31mdeoxycholate as initial therapy for cryptococcal meningitis, premedications to prevent infusion-related reactions were permitted. Am B isome-treated patients had a lower incidence of fever, [0m
[31mchills/rigors and respiratory adverse events as summarized in the following table: Incidence of Infusion-Related Reactions Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0[0m[31m. [0m
[31mAMBISOME: adverse_reactions: [0m[1;31m7[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m86[0m[31m [0m[1;31m94[0m[31m [0m[1;31m87[0m[31m Patients with fever increase of >[0m[1;31m1[0m[31mÂ°C [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m28[0m[31m%[0m[1;31m)[0m[31m Patients with [0m
[31mchills/rigors [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m42[0m[31m [0m[1;31m([0m[1;31m48[0m[31m%[0m[1;31m)[0m[31m Patients with nausea [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m13[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m18[0m[31m [0m[1;31m([0m[1;31m20[0m[31m%[0m[1;31m)[0m[31m Patients with vomiting [0m[1;31m14[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m Respiratory adverse events [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m There have been a few [0m
[31mreports of flushing, back pain with or without chest tightness, and chest pain associated with Am B isome administration; on occasion this has been severe. Where these symptoms were noted, the [0m
[31mreaction developed within a few minutes after the start of infusion and disappeared rapidly when the infusion was stopped. AMBISOME: adverse_reactions: The symptoms do not occur with every dose and [0m
[31musually do not recur on subsequent administrations when the infusion rate is slowed. Toxicity and Discontinuation of Dosing In Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m, a significantly lower incidence of grade [0m[1;31m3[0m[31m or [0m[1;31m4[0m[31m toxicity [0m
[31mwas observed in the Am B isome group compared with the amphotericin B group. In addition, nearly three times as many patients administered amphotericin B required a reduction in dose due to toxicity [0m
[31mor discontinuation of study drug due to an infusion-related reaction compared with those administered Am B isome. In empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, a greater proportion of patients in the [0m
[31mamphotericin B lipid complex group discontinued the study drug due to an adverse event than in the Am B isome groups. AMBISOME: adverse_reactions: Less Common Adverse Events The following adverse [0m
[31mevents also have been reported in [0m[1;31m2[0m[31m% to [0m[1;31m10[0m[31m% of Am B isome-treated patients receiving chemotherapy or bone marrow transplantation, or who had HIV disease in six comparative, clinical trials: Body as a [0m
[31mWhole Abdomen enlarged, allergic reaction, cellulitis, cell-mediated immunological reaction, face edema, graft-versus-host disease, malaise, neck pain, and procedural complication. Cardiovascular [0m
[31mSystem Arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, cardiomegaly, hemorrhage, postural hypotension, valvular heart disease, vascular disorder, and vasodilatation [0m[1;31m([0m[31mflushing[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: clinical_studies: One controlled trial compared the efficacy and safety of Am B isome to amphotericin B in HIV patients with cryptococcal meningitis. One compassionate use study [0m
[31menrolled patients who had failed amphotericin B deoxycholate therapy or who were unable to receive amphotericin B deoxycholate because of renal insufficiency. Empirical Therapy in Febrile Neutropenic [0m
[31mPatients Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m, a randomized, double-blind, comparative multi-center trial, evaluated the efficacy of Am B isome [0m[1;31m([0m[1;31m1.5[0m[31m-[0m[1;31m6[0m[31m mg/kg/day[0m[1;31m)[0m[31m compared with amphotericin B deoxycholate [0m[1;31m([0m[1;31m0.3[0m[31m-[0m[1;31m1.2[0m[31m [0m
[31mmg/kg/day[0m[1;31m)[0m[31m in the empirical treatment of [0m[1;31m687[0m[31m adult and pediatric neutropenic patients who were febrile despite having received at least [0m[1;31m96[0m[31m hours of broad spectrum antibacterial therapy. AMBISOME: [0m
[31mclinical_studies: Therapeutic success required [0m[1;31m([0m[31ma[0m[1;31m)[0m[31m resolution of fever during the neutropenic period, [0m[1;31m([0m[31mb[0m[1;31m)[0m[31m absence of an emergent fungal infection, [0m[1;31m([0m[31mc[0m[1;31m)[0m[31m patient survival for at least [0m[1;31m7[0m[31m days post [0m
[31mtherapy, [0m[1;31m([0m[31md[0m[1;31m)[0m[31m no discontinuation of therapy due to toxicity or lack of efficacy, and [0m[1;31m([0m[31me[0m[1;31m)[0m[31m resolution of any study-entry fungal infection. The overall therapeutic success rates for Am B isome and the [0m
[31mamphotericin B deoxycholate were equivalent. Results are summarized in the following table. Note: The categories presented below are not mutually exclusive. Empirical Therapy in Febrile Neutropenic [0m
[31mPatients: Randomized, Double-Blind Study in [0m[1;31m687[0m[31m Patients AmBisome [0m[1;31m3[0m[31m mg/kg/day Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day Number of patients receiving at least one dose of study drug [0m[1;31m343[0m[31m [0m[1;31m344[0m[31m Overall Success [0m[1;31m171[0m[31m [0m
[1;31m([0m[1;31m49.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m169[0m[31m [0m[1;31m([0m[1;31m49[0m[31m. AMBISOME: clinical_studies: [0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m Fever resolution during neutropenic period [0m[1;31m199[0m[31m [0m[1;31m([0m[1;31m58[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m200[0m[31m [0m[1;31m([0m[1;31m58.1[0m[31m%[0m[1;31m)[0m[31m No treatment-emergent fungal infection [0m[1;31m300[0m[31m [0m[1;31m([0m[1;31m87.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m301[0m[31m [0m[1;31m([0m[1;31m87.7[0m[31m%[0m[1;31m)[0m[31m Survival through [0m[1;31m7[0m[31m days[0m
[31mpost study drug [0m[1;31m318[0m[31m [0m[1;31m([0m[1;31m92.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m308[0m[31m [0m[1;31m([0m[1;31m89.5[0m[31m%[0m[1;31m)[0m[31m Study drug not prematurely discontinued due to toxicity or lack of efficacy* [0m[1;31m294[0m[31m [0m[1;31m([0m[1;31m85.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m280[0m[31m [0m[1;31m([0m[1;31m81.4[0m[31m%[0m[1;31m)[0m[31m * [0m[1;31m8[0m[31m and [0m[1;31m10[0m[31m patients, respectively, were treated as failures[0m
[31mdue to premature discontinuation alone. This therapeutic equivalence had no apparent relationship to the use of prestudy antifungal prophylaxis or concomitant granulocytic colony-stimulating factors. [0m
[31mThe incidence of mycologically-confirmed, and clinically-diagnosed, emergent fungal infections are presented in the following table. Am B isome and amphotericin B were found to be equivalent with [0m
[31mrespect to the total number of emergent fungal infections. AMBISOME: clinical_studies: Empirical Therapy in Febrile Neutropenic Patients: Emergent Fungal Infections AmBisome [0m[1;31m3[0m[31m mg/kg/day Amphotericin B[0m
[1;31m0.6[0m[31m mg/kg/day Number of patients receiving at least one dose of study drug [0m[1;31m343[0m[31m [0m[1;31m344[0m[31m Mycologically-confirmed fungal infection [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m3.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m27[0m[31m [0m[1;31m([0m[1;31m7.8[0m[31m%[0m[1;31m)[0m[31m Clinically-diagnosed fungal infection [0m[1;31m32[0m[31m [0m[1;31m([0m[1;31m9.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m
[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m Total emergent fungal infections [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m12.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m12.5[0m[31m%[0m[1;31m)[0m[31m Mycologically-confirmed fungal infections at study entry were cured in [0m[1;31m8[0m[31m of [0m[1;31m11[0m[31m patients in the Am B isome group and [0m[1;31m7[0m[31m of [0m[1;31m10[0m[31m in the [0m
[31mamphotericin B group. AMBISOME: clinical_studies: Study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, a randomized, double-blind, comparative multi-center trial, evaluated the safety of Am B isome [0m[1;31m([0m[1;31m3[0m[31m and [0m[1;31m5[0m[31m mg/kg/day[0m[1;31m)[0m[31m compared with [0m
[31mamphotericin B lipid complex [0m[1;31m([0m[1;31m5[0m[31m mg/kg/day[0m[1;31m)[0m[31m in the empirical treatment of [0m[1;31m202[0m[31m adult and [0m[1;31m42[0m[31m pediatric neutropenic patients. One hundred and sixty-six [0m[1;31m([0m[1;31m166[0m[1;31m)[0m[31m patients received Am B isome [0m[1;31m([0m[1;31m85[0m[31m patients [0m
[31mreceived [0m[1;31m3[0m[31m mg/kg/day and [0m[1;31m81[0m[31m received [0m[1;31m5[0m[31m mg/kg/day[0m[1;31m)[0m[31m and [0m[1;31m78[0m[31m patients received amphotericin B lipid complex. The study patients were febrile despite having received at least [0m[1;31m72[0m[31m hours of broad spectrum [0m
[31mantibacterial therapy. The primary endpoint of this study was safety. The study was not designed to draw statistically meaningful conclusions related to comparative efficacy and, in fact, Abelcet is [0m
[31mnot labeled for this indication.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: dosage_and_administration: DOSAGE AND ADMINISTRATION AmBisome is not interchangeable or substitutable on a mg per mg basis with other amphotericin B products. Different amphotericin[0m
[31mB products are not equivalent in terms of pharmacodynamics, pharmacokinetics and dosing. Am B isome should be administered by intravenous infusion, using a controlled infusion device, over a period of[0m
[31mapproximately [0m[1;31m120[0m[31m minutes. An in-line membrane filter may be used for the intravenous infusion of Am B isome, provided THE MEAN PORE DIAMETER OF THE FILTER IS NOT LESS THAN [0m[1;31m1.0[0m[31m MICRON . NOTE: An [0m
[31mexisting intravenous line must be flushed with [0m[1;31m5[0m[31m% Dextrose Injection prior to infusion of AmBisome. If this is not feasible, AmBisome must be administered through a separate line. Infusion time may be[0m
[31mreduced to approximately [0m[1;31m60[0m[31m minutes in patients in whom the treatment is well-tolerated. AMBISOME: dosage_and_administration: If the patient experiences discomfort during infusion, the duration of [0m
[31minfusion may be increased. The recommended initial dose of Am B isome for each indication for adult and pediatric patients is as follows: Indication Dose [0m[1;31m([0m[31mmg/kg/day[0m[1;31m)[0m[31m Empirical therapy [0m[1;31m3[0m[31m Systemic [0m
[31mfungal infections: Aspergillus Candida Cryptococcus [0m[1;31m3[0m[31m - [0m[1;31m5[0m[31m Cryptococcal meningitis in HIV-infected patients [0m[1;31m([0m[31msee DESCRIPTION OF CLINICAL STUDIES [0m[1;31m)[0m[31m [0m[1;31m6[0m[31m Dosing and rate of infusion should be individualized[0m
[31mto the needs of the specific patient to ensure maximum efficacy while minimizing systemic toxicities or adverse events. AMBISOME: dosage_and_administration: Doses recommended for visceral [0m
[31mleishmaniasis are presented below: Visceral Leishmaniasis Dose [0m[1;31m([0m[31mmg/kg/day[0m[1;31m)[0m[31m Immunocompetent patients [0m[1;31m3[0m[31m [0m[1;31m([0m[31mdays [0m[1;31m1[0m[31m - [0m[1;31m5[0m[1;31m)[0m[31m and [0m[1;31m3[0m[31m on days [0m[1;31m14[0m[31m, [0m[1;31m21[0m[31m Immunocompromised patients [0m[1;31m4[0m[31m [0m[1;31m([0m[31mdays [0m[1;31m1[0m[31m - [0m[1;31m5[0m[1;31m)[0m[31m and [0m[1;31m4[0m[31m on days [0m[1;31m10[0m[31m, [0m[1;31m17[0m[31m, [0m
[1;31m24[0m[31m, [0m[1;31m31[0m[31m, [0m[1;31m38[0m[31m For immunocompetent patients who do not achieve parasitic clearance with the recommended dose, a repeat course of therapy may be useful. For immunocompromised patients who do not clear [0m
[31mparasites or who experience relapses, expert advice regarding further treatment is recommended. For additional information, see DESCRIPTION OF CLINICAL STUDIES .         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions_table: <table [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><caption>Laboratory Evidence of Nephrotoxicity Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m<[0m[31m/[0m[31mcaption[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"20[0m[31m%"[0m[31m/[0m[31m><col [0m[31mwidth[0m[31m=[0m[31m"21[0m[31m%"[0m[31m/[0m[31m><col [0m
[31mwidth[0m[31m=[0m[31m"18[0m[31m%"[0m[31m/[0m[31m><tbody><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m/[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>AmBisome <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>[0m[1;31m3[0m[31m mg/kg/day<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Botrule Lrule Toprule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>AmBisome <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>[0m[1;31m6[0m[31m mg/kg/day<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m [0m
[31mBotrule Lrule AMBISOME: adverse_reactions_table: Toprule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Amphotericin B<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>[0m[1;31m0[0m[31m. AMBISOME: [0m
[31madverse_reactions_table: [0m[1;31m7[0m[31m mg/kg/day<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Toprule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Total number of patients receiving at least one dose of [0m
[31mstudy drug<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Toprule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m><paragraph> [0m[1;31m86[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Toprule Botrule "[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m><paragraph>[0m[1;31m94[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Toprule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m><paragraph>[0m[1;31m87[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"4"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Toprule Botrule "[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m><paragraph>Number with Nephrotoxicity [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m<[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr[0m[1;31m>[0m[31m<td [0m[31mstyleCode[0m[31m=[0m[31m"Rrule[0m[31m Lrule Toprule Botrule "[0m[31m         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions: ADVERSE REACTIONS The following adverse events are based on the experience of [0m[1;31m592[0m[31m adult patients [0m[1;31m([0m[1;31m295[0m[31m treated with Am B isome and [0m[1;31m297[0m[31m treated with amphotericin B [0m
[31mdeoxycholate[0m[1;31m)[0m[31m and [0m[1;31m95[0m[31m pediatric patients [0m[1;31m([0m[1;31m48[0m[31m treated with Am B isome and [0m[1;31m47[0m[31m treated with amphotericin B deoxycholate[0m[1;31m)[0m[31m in Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m, a randomized double-blind, multi-center study in febrile, [0m
[31mneutropenic patients. Am B isome and amphotericin B were infused over two hours. AMBISOME: adverse_reactions: The incidence of common adverse events [0m[1;31m([0m[31mincidence of [0m[1;31m10[0m[31m% or greater[0m[1;31m)[0m[31m occurring with Am B [0m
[31misome compared to amphotericin B deoxycholate, regardless of relationship to study drug, is shown in the following table: Empirical Therapy Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m Common Adverse Events Adverse Event by Body [0m
[31mSystem AmBisome N = [0m[1;31m343[0m[31m % Amphotericin B N = [0m[1;31m344[0m[31m % Body as a Whole Abdominal pain Asthenia Back pain Blood product transfusion reaction Chills Infection Pain Sepsis [0m[1;31m19.8[0m[31m [0m[1;31m13.1[0m[31m [0m[1;31m12[0m[31m [0m[1;31m18.4[0m[31m [0m[1;31m47.5[0m[31m [0m[1;31m11.1[0m[31m [0m[1;31m14[0m[31m [0m[1;31m14[0m[31m [0m
[1;31m21.8[0m[31m [0m[1;31m10.8[0m[31m [0m[1;31m7.3[0m[31m [0m[1;31m18.6[0m[31m [0m[1;31m75.9[0m[31m [0m[1;31m9.3[0m[31m [0m[1;31m12.8[0m[31m [0m[1;31m11.3[0m[31m Cardiovascular System Chest pain Hypertension Hypotension Tachycardia [0m[1;31m12[0m[31m [0m[1;31m7.9[0m[31m [0m[1;31m14.3[0m[31m [0m[1;31m13[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m4[0m[31m [0m[1;31m11.6[0m[31m [0m[1;31m16.3[0m[31m [0m[1;31m21.5[0m[31m [0m[1;31m20.9[0m[31m Digestive System Diarrhea[0m
[31mGastrointestinal hemorrhage Nausea Vomiting [0m[1;31m30.3[0m[31m [0m[1;31m9.9[0m[31m [0m[1;31m39.7[0m[31m [0m[1;31m31.8[0m[31m [0m[1;31m27.3[0m[31m [0m[1;31m11.3[0m[31m [0m[1;31m38.7[0m[31m [0m[1;31m43.9[0m[31m Metabolic and Nutritional Disorders Alkaline phosphatase increased ALT [0m[1;31m([0m[31mSGPT[0m[1;31m)[0m[31m increased AST [0m[1;31m([0m[31mSGOT[0m[1;31m)[0m[31m increased [0m
[31mBilirubinemia BUN increased Creatinine increased Edema Hyperglycemia Hypernatremia Hypervolemia Hypocalcemia Hypokalemia Hypomagnesemia Peripheral edema [0m[1;31m22.2[0m[31m [0m[1;31m14.6[0m[31m [0m[1;31m12.8[0m[31m [0m[1;31m18.1[0m[31m [0m[1;31m21[0m[31m [0m[1;31m22.4[0m[31m [0m[1;31m14.3[0m[31m [0m[1;31m23[0m[31m [0m[1;31m4.1[0m[31m [0m[1;31m12.2[0m[31m [0m
[1;31m18.4[0m[31m [0m[1;31m42.9[0m[31m [0m[1;31m20.4[0m[31m [0m[1;31m14.6[0m[31m [0m[1;31m19.2[0m[31m [0m[1;31m14[0m[31m [0m[1;31m12.8[0m[31m [0m[1;31m19[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m2[0m[31m [0m[1;31m31.1[0m[31m [0m[1;31m42.2[0m[31m [0m[1;31m14.8[0m[31m [0m[1;31m27.9[0m[31m [0m[1;31m11[0m[31m [0m[1;31m15.4[0m[31m [0m[1;31m20.9[0m[31m [0m[1;31m50.6[0m[31m [0m[1;31m25.6[0m[31m [0m[1;31m17.2[0m[31m Nervous System Anxiety Confusion Headache Insomnia [0m[1;31m13.7[0m[31m [0m[1;31m11.4[0m[31m [0m[1;31m19.8[0m[31m [0m[1;31m17.2[0m[31m [0m[1;31m11[0m[31m [0m[1;31m13.4[0m[31m [0m[1;31m20.9[0m[31m [0m
[1;31m14.2[0m[31m Respiratory System Cough increased Dyspnea Epistaxis Hypoxia Lung disorder Pleural effusion Rhinitis [0m[1;31m17.8[0m[31m [0m[1;31m23[0m[31m [0m[1;31m14.9[0m[31m [0m[1;31m7.6[0m[31m [0m[1;31m17.8[0m[31m [0m[1;31m12.5[0m[31m [0m[1;31m11.1[0m[31m [0m[1;31m21.8[0m[31m [0m[1;31m29.1[0m[31m [0m[1;31m20.1[0m[31m [0m[1;31m14.8[0m[31m [0m[1;31m17.4[0m[31m [0m[1;31m9.6[0m[31m [0m[1;31m11[0m[31m Skin and Appendages Pruritus [0m
[31mRash Sweating [0m[1;31m10.8[0m[31m [0m[1;31m24.8[0m[31m [0m[1;31m7[0m[31m [0m[1;31m10.2[0m[31m [0m[1;31m24.4[0m[31m [0m[1;31m10[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m8[0m[31m Urogenital System Hematuria [0m[1;31m14[0m[31m [0m[1;31m14[0m[31m Am B isome was well tolerated. Am B isome had a lower incidence of chills, hypertension, [0m
[31mhypotension, tachycardia, hypoxia, hypokalemia, and various events related to decreased kidney function as compared to amphotericin B deoxycholate. In pediatric patients [0m[1;31m([0m[1;31m16[0m[31m years of age or less[0m[1;31m)[0m[31m in [0m
[31mthis double-blind study, Am B isome compared to amphotericin B deoxycholate, had a lower incidence of hypokalemia [0m[1;31m([0m[1;31m37[0m[31m% versus [0m[1;31m55[0m[31m%[0m[1;31m)[0m[31m, chills [0m[1;31m([0m[1;31m29[0m[31m% versus [0m[1;31m68[0m[31m%[0m[1;31m)[0m[31m, vomiting [0m[1;31m([0m[1;31m27[0m[31m% versus [0m[1;31m55[0m[31m%[0m[1;31m)[0m[31m, and hypertension[0m
[1;31m([0m[1;31m10[0m[31m% versus [0m[1;31m21[0m[31m%[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The provided extracts from the AMBISOME label do not specifically mention acute liver injury as an adverse reaction. However, they do mention that the frequency and magnitude of hepatic test [0m
[32mabnormalities were similar in the AMBISOME and amphotericin B groups, suggesting that AMBISOME does not significantly increase the risk of hepatic issues compared to amphotericin B. Additionally, the [0m
[32mextracts focus on nephrotoxicity and other adverse reactions, but acute liver injury is not listed among the common or less common adverse events.[0m

[32mSOURCE: AMBISOME label[0m
[32mEXTRACT_START_END: The frequency and magnitude of hepatic test abnormalities [0m[32m...[0m[32m similar in the AMBISOME and amphotericin B groups.[0m
*[1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The provided extracts from the AMBISOME label do not [0m
[34mspecifically mention acute liver injury as an adverse reaction. However, they do mention that the frequency and magnitude of hepatic test abnormalities were similar in the AMBISOME and amphotericin B [0m
[34mgroups, suggesting that AMBISOME does not significantly increase the risk of hepatic issues compared to amphotericin B. Additionally, the extracts focus on nephrotoxicity and other adverse reactions, [0m
[34mbut acute liver injury is not listed among the common or less common adverse events.[0m

[34mSOURCE: AMBISOME label[0m
[34mEXTRACT_START_END: The frequency and magnitude of hepatic test abnormalities [0m[34m...[0m[34m similar in the AMBISOME and amphotericin B groups.[0m
 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether AMBISOME increases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the AMBISOME label does not specifically mention acute liver injury as an adverse reaction. However, it was noted that the frequency and magnitude of hepatic test [0m
[32mabnormalities were similar in the AMBISOME and amphotericin B groups, suggesting that AMBISOME does not significantly increase the risk of hepatic issues compared to amphotericin B."[0m[32m,[0m
[32m      [0m[32m"The label focuses on nephrotoxicity and other adverse reactions, but acute liver injury is not listed among the common or less common adverse events."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"Based on the information provided by FDAHandler, AMBISOME does not specifically list acute liver injury as an adverse reaction, and the risk of hepatic issues does not appear to be [0m
[32msignificantly increased compared to amphotericin B. Therefore, it is not indicated that AMBISOME increases the risk of acute liver injury."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does AMBISOME increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether AMBISOME increases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the AMBISOME label does not specifically mention acute liver injury as an adverse reaction. However, it was noted that the frequency and magnitude of hepatic test [0m
[34mabnormalities were similar in the AMBISOME and amphotericin B groups, suggesting that AMBISOME does not significantly increase the risk of hepatic issues compared to amphotericin B."[0m[34m,[0m
[34m      [0m[34m"The label focuses on nephrotoxicity and other adverse reactions, but acute liver injury is not listed among the common or less common adverse events."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"Based on the information provided by FDAHandler, AMBISOME does not specifically list acute liver injury as an adverse reaction, and the risk of hepatic issues does not appear to be [0m
[34msignificantly increased compared to amphotericin B. Therefore, it is not indicated that AMBISOME increases the risk of acute liver injury."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does AMBISOME increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether AMBISOME increases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler responded that the AMBISOME label does not specifically mention acute liver injury as an adverse reaction. However, it was noted that the frequency and magnitude of hepatic test [0m
[31mabnormalities were similar in the AMBISOME and amphotericin B groups, suggesting that AMBISOME does not significantly increase the risk of hepatic issues compared to amphotericin B.[0m
[1;31m3[0m[31m. The label focuses on nephrotoxicity and other adverse reactions, but acute liver injury is not listed among the common or less common adverse events.[0m
[31m        -----[0m
[31m        Final answer: Based on the information provided by FDAHandler, AMBISOME does not specifically list acute liver injury as an adverse reaction, and the risk of hepatic issues does not appear to [0m
[31mbe significantly increased compared to amphotericin B. Therefore, it is not indicated that AMBISOME increases the risk of acute liver injury.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does AMBISOME increase or decrease the risk of acute liver injury?"[0m[32m is that, based on the information provided by FDAHandler, AMBISOME does not specifically list [0m
[32macute liver injury as an adverse reaction. The frequency and magnitude of hepatic test abnormalities were reported to be similar in the AMBISOME and amphotericin B groups, suggesting that AMBISOME [0m
[32mdoes not significantly increase the risk of hepatic issues compared to amphotericin B. Therefore, it is not indicated that AMBISOME increases the risk of acute liver injury.[0m
